http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 12 Jun 2026 16:31:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+11++Filed+by%3A+Lochner+Daniel/26641384.html si-local-file:///var/storage/secattach/20260612/26641384.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+11++Filed+by%3A+Lochner+Daniel/26641384.html Fri, 12 Jun 2026 16:31:00 -0400 O.29707909 TECX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+11++Filed+by%3A+Lochner+Daniel/26641384.html si-local-file:///var/storage/secattach/20260612/26641384.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+11++Filed+by%3A+Lochner+Daniel/26641384.html Fri, 12 Jun 2026 16:31:00 -0400 O.29707909 TECX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+08/26630805.html si-local-file:///var/storage/secattach/20260610/26630805.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+08/26630805.html Wed, 10 Jun 2026 17:09:00 -0400 O.29707909 TECX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+08/26630805.html si-local-file:///var/storage/secattach/20260610/26630805.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+08/26630805.html Wed, 10 Jun 2026 17:09:00 -0400 O.29707909 TECX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+09++Filed+by%3A+Donenberg+Phillip+B./26630555.html si-local-file:///var/storage/secattach/20260610/26630555.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+09++Filed+by%3A+Donenberg+Phillip+B./26630555.html Wed, 10 Jun 2026 16:45:00 -0400 O.29707909 TECX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+09++Filed+by%3A+Donenberg+Phillip+B./26630555.html si-local-file:///var/storage/secattach/20260610/26630555.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+09++Filed+by%3A+Donenberg+Phillip+B./26630555.html Wed, 10 Jun 2026 16:45:00 -0400 O.29707909 TECX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+09++Filed+by%3A+Tipirneni+Praveen+P./26630556.html si-local-file:///var/storage/secattach/20260610/26630556.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+09++Filed+by%3A+Tipirneni+Praveen+P./26630556.html Wed, 10 Jun 2026 16:45:00 -0400 O.29707909 TECX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+09++Filed+by%3A+Tipirneni+Praveen+P./26630556.html si-local-file:///var/storage/secattach/20260610/26630556.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+09++Filed+by%3A+Tipirneni+Praveen+P./26630556.html Wed, 10 Jun 2026 16:45:00 -0400 O.29707909 TECX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+09++Filed+by%3A+SPRINGER+TIMOTHY+A/26630557.html si-local-file:///var/storage/secattach/20260610/26630557.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+09++Filed+by%3A+SPRINGER+TIMOTHY+A/26630557.html Wed, 10 Jun 2026 16:45:00 -0400 O.29707909 TECX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+09++Filed+by%3A+SPRINGER+TIMOTHY+A/26630557.html si-local-file:///var/storage/secattach/20260610/26630557.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+09++Filed+by%3A+SPRINGER+TIMOTHY+A/26630557.html Wed, 10 Jun 2026 16:45:00 -0400 O.29707909 TECX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+09++Filed+by%3A+Vitorovic+Stefan/26630558.html si-local-file:///var/storage/secattach/20260610/26630558.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+09++Filed+by%3A+Vitorovic+Stefan/26630558.html Wed, 10 Jun 2026 16:45:00 -0400 O.29707909 TECX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+09++Filed+by%3A+Vitorovic+Stefan/26630558.html si-local-file:///var/storage/secattach/20260610/26630558.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+09++Filed+by%3A+Vitorovic+Stefan/26630558.html Wed, 10 Jun 2026 16:45:00 -0400 O.29707909 TECX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+08++Filed+by%3A+Chutter+Jessica+Caroline/26630438.html si-local-file:///var/storage/secattach/20260610/26630438.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+08++Filed+by%3A+Chutter+Jessica+Caroline/26630438.html Wed, 10 Jun 2026 16:36:00 -0400 O.29707909 TECX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+08++Filed+by%3A+Chutter+Jessica+Caroline/26630438.html si-local-file:///var/storage/secattach/20260610/26630438.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+08++Filed+by%3A+Chutter+Jessica+Caroline/26630438.html Wed, 10 Jun 2026 16:36:00 -0400 O.29707909 TECX http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+08++Filed+by%3A+Chutter+Jessica+Caroline/26630425.html si-local-file:///var/storage/secattach/20260610/26630425.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+08++Filed+by%3A+Chutter+Jessica+Caroline/26630425.html Wed, 10 Jun 2026 16:35:00 -0400 O.29707909 TECX http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+08++Filed+by%3A+Chutter+Jessica+Caroline/26630425.html si-local-file:///var/storage/secattach/20260610/26630425.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Tectonic+Therapeutic%2C+++++For%3A+Jun+08++Filed+by%3A+Chutter+Jessica+Caroline/26630425.html Wed, 10 Jun 2026 16:35:00 -0400 O.29707909 TECX http://www.streetinsider.com/FDA/Tectonic+Therapeutic+completes+enrollment+in+TX45+phase+2+trial/26629714.html <p>Tectonic Therapeutic Inc. (NASDAQ: TECX) completed enrollment in its APEX Phase 2 clinical trial evaluating TX45 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction.</p> <p>The 24-week trial enrolled 191 patients across 14 countries, with 137 patients having combined pre- and post-capillary pulmonary hypertension and pulmonary vascular resistance greater than 3 Wood Units at baseline. This population represents approximately 72% of total enrolled patients.</p> <p>The randomized, double-blind, placebo-controlled trial is testing two dose regimens of TX45 administered subcutaneously. Patients receive either 300 mg monthly, 300 mg every other week, or placebo. The primary endpoint measures change from baseline http://www.streetinsider.com/FDA/Tectonic+Therapeutic+completes+enrollment+in+TX45+phase+2+trial/26629714.html Wed, 10 Jun 2026 16:01:13 -0400 TECX http://www.streetinsider.com/Press+Releases/Tectonic+Therapeutic+Completes+Enrollment+in+TX45+APEX+Phase+2+Clinical+Trial+in+PH-HFpEF+Patients/26629708.html <ul><li>APEX 24-week Phase 2 trial is evaluating the safety and efficacy of TX45 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF)</li><li style="margin-bottom:8pt;">APEX Phase 2 trial enrolled 191 patients across 14 countries, with approximately 72% of patients in the enriched population of CpcPH with a pulmonary vascular resistance (PVR) <u>&gt;</u>3 WU at baseline</li><li style="margin-bottom:8pt;">TX45 APEX Phase 2 topline results expected in early Q1 2027<br /><br /></li></ul> <p>WATERTOWN, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=3B-hTUX_k0WdbY3nuGhxn7lCWyCFP6RsEGlYPQBevQH2b3x_83B66oi3cPrcL3JTRyVnQY2NfE-UPwuyp97uthucew06OWi38CQ1HSYN9to=" rel="nofollow" target="_blank">Tectonic Therapeutic, Inc. </a>(NASDAQ: TECX) (“Tectonic” or the “Company”), a clinical stage biotechnology company focused on http://www.streetinsider.com/Press+Releases/Tectonic+Therapeutic+Completes+Enrollment+in+TX45+APEX+Phase+2+Clinical+Trial+in+PH-HFpEF+Patients/26629708.html Wed, 10 Jun 2026 16:01:00 -0400 TECX http://www.streetinsider.com/Globe+Newswire/Tectonic+Therapeutic+Completes+Enrollment+in+TX45+APEX+Phase+2+Clinical+Trial+in+PH-HFpEF+Patients/26629708.html <ul><li>APEX 24-week Phase 2 trial is evaluating the safety and efficacy of TX45 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF)</li><li style="margin-bottom:8pt;">APEX Phase 2 trial enrolled 191 patients across 14 countries, with approximately 72% of patients in the enriched population of CpcPH with a pulmonary vascular resistance (PVR) <u>&gt;</u>3 WU at baseline</li><li style="margin-bottom:8pt;">TX45 APEX Phase 2 topline results expected in early Q1 2027<br /><br /></li></ul> <p>WATERTOWN, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=3B-hTUX_k0WdbY3nuGhxn7lCWyCFP6RsEGlYPQBevQH2b3x_83B66oi3cPrcL3JTRyVnQY2NfE-UPwuyp97uthucew06OWi38CQ1HSYN9to=" rel="nofollow" target="_blank">Tectonic Therapeutic, Inc. </a>(NASDAQ: TECX) (“Tectonic” or the “Company”), a clinical stage biotechnology company focused on http://www.streetinsider.com/Globe+Newswire/Tectonic+Therapeutic+Completes+Enrollment+in+TX45+APEX+Phase+2+Clinical+Trial+in+PH-HFpEF+Patients/26629708.html Wed, 10 Jun 2026 16:01:00 -0400 TECX http://www.streetinsider.com/Hot+List+Pro/This+stock+%22offers+an+uncommonly+attractive+opportunity%22%3A+analyst/26551784.html <p>Investing.com -- Raymond James upgraded Tectonic Therapeutic, Inc. to “Strong Buy” from “Outperform” and raised its price target to $81 from $76, citing growing confidence in the company’s pipeline and especially its experimental HHT therapy, TX2100.</p><p>The brokerage said Tectonic’s valuation remains attractive, with the biotech trading at an enterprise value of roughly $300 million despite having two clinical-stage assets with blockbuster potential. Analysts noted the company’s $237 million cash position should fund operations into late 2028.</p><p>Raymond James highlighted TX2100, an APJ antagonist being developed for hereditary hemorrhagic telangiectasia (HHT), as a key driver of future upside. HHT is a rare http://www.streetinsider.com/Hot+List+Pro/This+stock+%22offers+an+uncommonly+attractive+opportunity%22%3A+analyst/26551784.html Tue, 26 May 2026 19:00:00 -0400 TECX http://www.streetinsider.com/Hot+List/This+stock+%22offers+an+uncommonly+attractive+opportunity%22%3A+analyst/26551784.html <p>Investing.com -- Raymond James upgraded Tectonic Therapeutic, Inc. to “Strong Buy” from “Outperform” and raised its price target to $81 from $76, citing growing confidence in the company’s pipeline and especially its experimental HHT therapy, TX2100.</p><p>The brokerage said Tectonic’s valuation remains attractive, with the biotech trading at an enterprise value of roughly $300 million despite having two clinical-stage assets with blockbuster potential. Analysts noted the company’s $237 million cash position should fund operations into late 2028.</p><p>Raymond James highlighted TX2100, an APJ antagonist being developed for hereditary hemorrhagic telangiectasia (HHT), as a key driver of future upside. HHT is a rare http://www.streetinsider.com/Hot+List/This+stock+%22offers+an+uncommonly+attractive+opportunity%22%3A+analyst/26551784.html Tue, 26 May 2026 19:00:00 -0400 TECX http://www.streetinsider.com/Upgrades/Raymond+James+Upgrades+Tectonic+Therapeutics+Inc.+%28TECX%29+to+Strong+Buy/26544784.html <p>Raymond James analyst Martin Auster upgraded Tectonic Therapeutics Inc. (NASDAQ: TECX) from Outperform to Strong Buy with a price target of $81.00 (from $76.00).</p><p>The analyst comments: “We are upgrading Tectonic Therapeutic to a Strong Buy rating and raising our target price to $81. Tectonic offers an uncommonly attractive opportunity trading at an EV of ~$300M with two potential blockbuster clinical-stage pipeline assets; cash of $237M ($12/sh) supports a runway into late 2028. While TX45 and TX2100 will need incremental de-risking for investors to realize a major upside valuation reset, the potential is clearly there as both programs are built on http://www.streetinsider.com/Upgrades/Raymond+James+Upgrades+Tectonic+Therapeutics+Inc.+%28TECX%29+to+Strong+Buy/26544784.html Tue, 26 May 2026 03:48:12 -0400 TECX http://www.streetinsider.com/Analyst+Comments/Raymond+James+Upgrades+Tectonic+Therapeutics+Inc.+%28TECX%29+to+Strong+Buy/26544784.html <p>Raymond James analyst Martin Auster upgraded Tectonic Therapeutics Inc. (NASDAQ: TECX) from Outperform to Strong Buy with a price target of $81.00 (from $76.00).</p><p>The analyst comments: “We are upgrading Tectonic Therapeutic to a Strong Buy rating and raising our target price to $81. Tectonic offers an uncommonly attractive opportunity trading at an EV of ~$300M with two potential blockbuster clinical-stage pipeline assets; cash of $237M ($12/sh) supports a runway into late 2028. While TX45 and TX2100 will need incremental de-risking for investors to realize a major upside valuation reset, the potential is clearly there as both programs are built on http://www.streetinsider.com/Analyst+Comments/Raymond+James+Upgrades+Tectonic+Therapeutics+Inc.+%28TECX%29+to+Strong+Buy/26544784.html Tue, 26 May 2026 03:48:12 -0400 TECX http://www.streetinsider.com/Earnings/Tectonic+Therapeutic+%28TECX%29+Misses+Q1+EPS+by+134c/26455699.html <p>Tectonic Therapeutic (NASDAQ: TECX) reported Q1 EPS of ($1.34).</p><p>For earnings history and earnings-related data on Tectonic Therapeutic (TECX) <a href="http://www.streetinsider.com/ec_earnings.php?q=TECX">click here</a>.</p> http://www.streetinsider.com/Earnings/Tectonic+Therapeutic+%28TECX%29+Misses+Q1+EPS+by+134c/26455699.html Thu, 07 May 2026 18:37:01 -0400 TECX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Tectonic+Therapeutic%2C+++++For%3A+May+07/26454053.html si-local-file:///var/storage/secattach/20260507/26454053.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Tectonic+Therapeutic%2C+++++For%3A+May+07/26454053.html Thu, 07 May 2026 16:25:00 -0400 O.29707909 TECX